China’s official PMIs jumped back into expansionary territory

China’s official NBS PMIs bounced back in March. The manufacturing PMI rose to 52.0, up from 35.7, while the non-manufacturing increased to 52.3 after 29.6 in February. By their very construction, a strong rebound had to be expected. PMI surveys essentially ask whether firm’s businesses have been better or worse compared to the previous month.

Highlights:

  • This morning, China’s official NBS manufacturing and non-man. PMIs jumped back into expansionary territory.
  • While this confirms China’s economy has likely started to bottom out from the Covid-19 crisis, the outlook will depend on three factors:
    • The ongoing normalization in production and consumer demand: While production will likely reach normal capacity utilization in mid-April (provided new corona cases remain on low levels) private consumption is still lagging.
    • The global recession: We strongly revised down our 2020 global GDP forecasts (to -1%) which will result in weak Chinese exports.
    • An additional fiscal package: Last Friday’s politburo meeting fueled expectations that a package will be announced shortly. We expect total stimulus of around 3.5% – 4% of GDP.
  • In sum, we see China’s growth subdued this year at 2.5%. We stress that this forecast comes with an unusually high degree of uncertainty.

Download the full publication below

CHINA’S OFFICIAL PMIS JUMPED BACK INTO EXPANSIONARY TERRITORY

RELATED INSIGHTS

A (TEMPORARY) COVID ‘LEG DOWN’
The rise in new Covid-19 cases and renewed lockdowns across Europe are casting long shadows over the economic recovery and markets. Yet much more targeted restrictions, a strong Chinese rebound and continued massive fiscal and monetary policy support will keep the second wave’s impact far more muted than in spring.
COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients.
INCORPORATING QUANT SIGNALS INTO EU EQUITY SECTOR/STYLE STRATEGY: MAINTAIN A TILT TO CYCLICALS AND VALUE
We present an update of our proprietary equity valuation tool, based on quant models. It provides indications of over- or undervaluation for different sectors and styles of European equities, which is further enriched by our qualitative analysis.